Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mechanical Prosthetic Valve Thrombosis: A Literature Review of Treatment Strategies Publisher Pubmed



Ebrahimi P1 ; Sattartabar B1 ; Taheri H2 ; Soltani P1 ; Bahiraie P3 ; Mousavinezhad SM4 ; Gooshvar M4 ; Kampaktsis P5 ; Arsanjani R6 ; Sahebjam M1 ; Hosseini K1 ; Siegel RJ2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, United States
  3. 3. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  5. 5. Division of Cardiology, Columbia University Irving Medical Center, NYC, NY, United States
  6. 6. Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, 85054, AZ, United States

Source: Current Problems in Cardiology Published:2024


Abstract

Mechanical prosthetic valve thrombosis (MPVT) is a common complication of valvular implantations. This study compared the efficacy and safety of different treatments for MPVT. A systematic search of electronic databases identified studies evaluating surgical, anticoagulant, and thrombolytic therapies. Although several studies of different types have been conducted to evaluate the efficacy of these treatment strategies the lack of randomized controlled trials has resulted in the inability to make a definitive conclusion about the pros and cons of these treatments. Recent treatments, such as slow and ultraslow infusion of thrombolytics, showed comparable efficacy and lower complication rates than traditional methods. Inadequate anticoagulant use is a major risk factor for MPVT, highlighting the importance of prevention. Treatment selection should be individualized based on patient factors and available expertise. Overall, slow and ultraslow infusion of thrombolytics may be a promising treatment option for MPVT. © 2024 Elsevier Inc.